Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Bayer Files Kerendia in Japan for Broader CKD Use
Bayer Yakuhin said on August 28 that it has filed its selective non-steroidal mineralocorticoid receptor antagonist Kerendia (finerenone) in Japan for an expansion of its chronic kidney disease (CKD) indication to cover patients without diabetes. Kerendia is currently indicated in…
To read the full story
Related Article
- Bayer Eyes Kerendia as Standard Therapy for CKM Syndrome
February 20, 2026
- Bayer Rolls Out CKD Drug Kerendia in Japan
June 3, 2022
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…